Company Overview and News


Add BIOC
to your dashboard

Headline News

BRIEF-Biocept files for offering $10 mln of shares of co's common stock and warrants

2017-11-17 reuters
* Biocept Inc files for offering $10 million of shares of co’s common stock and warrants - SEC Filing (17-2)

Biocept's (BIOC) CEO Michael Nall on Q3 2017 Results - Earnings Call Transcript

2017-11-11 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Biocept 2017 Third Quarter Conference Call. (17-0)

Renowned Lung Cancer Expert Joins Biocept's Clinical Advisory Board

2017-10-11 devicespace
SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that Fred R. Hirsch, M.D., Ph.D. has joined its Clinical Advisory Board.  Dr. Hirsch is Professor of Medicine and Pathology at the University of Colorado Cancer Center. (32-1)

Renowned Lung Cancer Expert Fred R. Hirsch, M.D., Ph.D. Joins Biocept's Clinical Advisory Board

2017-10-11 prnewswire
SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that Fred R. Hirsch, M.D., Ph.D. has joined its Clinical Advisory Board.  Dr. Hirsch is Professor of Medicine and Pathology at the University of Colorado Cancer Center. (32-1)

Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

2017-10-03 prnewswire
MLS to market Biocept's proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future (32-2)

Biocept And Miraca Life Sciences Enter Into Marketing Agreement To Expand Target Selector Testing In The United States

2017-10-03 devicespace
SAN DIEGO, Oct. 3, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered into a Promotion and Marketing Agreement with Miraca Life Sciences, Inc. (MLS) to market Biocept's Target Selector liquid biopsy tests and services to community-based oncologists and hematologists in specified sales territories in the United States. (32-1)

5 Medtech Stocks to Steer Clear of Amid Political Chaos

2017-09-19 zacks
Since the change in political power in the United States, it has been quite a tumultuous phase for MedTech. Things started getting dramatic since President Trump started forging ahead with his plans to repeal Obamacare. After a series of futile attempts, the Republicans resorted to a “skinny repeal” of Obamacare which failed as well. (35-1)

Biocept and UT Southwestern Medical Center Announce Clinical Study to Profile and Monitor Non-Small Cell Lung Cancer Patients with ALK Rearrangements

2017-08-17 prnewswire
Leading clinical investigator to utilize Biocept's liquid biopsy tests for the detection of ALK rearrangements at baseline and to monitor treatment response and resistance mechanisms over time (0-1)

Biocept Enters Into Exclusive Distribution Agreement With Global Laboratory Product Supplier VWR

2017-08-14 devicespace
SAN DIEGO, Aug. 14, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has signed an exclusive global Distribution Agreement excluding China, for the Company's proprietary blood collection tubes (BCTs) with VWR International, LLC (VWR), the leading global independent provider of product and service solutions to laboratory and production customers.

BRIEF-Biocept enters into distribution agreement with Global Laboratory Product Supplier VWR

2017-08-14 reuters
* Biocept Inc - commercial launch is anticipated to begin in second half of 2017. Source text for Eikon: Further company coverage: (0-1)

Biocept Enters Into Exclusive Distribution Agreement with Global Laboratory Product Supplier VWR

2017-08-14 prnewswire
Patented blood collection tubes developed by Biocept validated to preserve ctDNA for up to 96 hours at room temperature allowing for intact shipping of liquid biopsy samples from regions around the world

Week In Review: Zai Lab Targets $1 Billion Valuation In Planned U.S. IPO

2017-08-13 seekingalpha
Shanghai's Zai Lab is planning a US IPO that could raise $150 million and value the company at $1 billion, according to knowledgeable sources (see story). The company has already picked Citigroup and JPMorgan Chase as underwriters, though it has not completed a US filing. Zai Lab is led by high-profile Samantha Du, PhD, who previously was responsible for Chi-Med's innovative drug R&D operations. Zai is developing innovative products with an eye toward the China market in oncology, autoimmune and infectious disease areas. (0-1)

Medical Laboratories Stocks on Investors' Radar -- DexCom, Novadaq Technologies, Biocept, and Exact Sciences

2017-08-11 prnewswire
If you want a Stock Review on DXCM, NVDQ, BIOC, or EXAS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Thursday, August 10, 2017, US markets saw broad based losses with eight out of nine sectors finishing the trading sessions in red. Major US indices were also bearish at the close of yesterday's session. The NASDAQ Composite ended the day at 6,216.

Biocept's (BIOC) CEO Michael Nall on Q2 2017 Results - Earnings Call Transcript

2017-08-11 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Biocept 2017 Second Quarter Conference Call.

Biocept Reports Second Quarter 2017 Financial Results

2017-08-10 prnewswire
- Reported revenues of $1.3 million in 2Q 2017 vs. $663,000 in 2Q 2016, up 93%, or 64% excluding the impact of conversion to accrual-based revenue recognition - Launch of "AND" campaign supports growth in test volume both sequentially and year-over-year - New provider agreements with both Scripps Health Plan and MediNcrease expand patient access to Biocept's proprietary liquid biopsy test platform - Secures $2.

Stock Research Report

Biocept is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or “liquid biopsy.” its current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic mutations that may qualify a subset of cancer patients for targeted therapy. Often, traditional methodologies such as tissue biopsies are insufficient or unavailable to provide the molecular subtype information necessary for clinical decisions. Biocept assays have the potential to provide more contemporaneous information on the characteristics of a patient’s disease compared with traditional methodologies such as tissue biopsy and radiographic imaging.

Biocept current assays and planned future assays focus on key solid tumor indications utilizing its Target-Selectors liquid biopsy technology platform for the biomarker anal...

Click for full article
CUSIP: 09072V105